Drugs / SB17170
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06846684 | Mar → Jun 2025 | — | SPARK Biopharma | Completed | No outcome recorded |
| Phase 1 | NCT05795192 | May 2023 → Feb 2024 | — | SPARK Biopharma | Completed | No outcome recorded |
| Phase 1 | NCT05522868 | Oct 2022 → Jun 2027 expected | cancer | SPARK Biopharma | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06747923 | Jan 2025 → May 2026 overdue | idiopathic pulmonary fibrosis | SPARK Biopharma | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SB17170 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06846684 ↗ |
| Route | Oral | “Oral administration 21days/cycle” NCT05522868 ↗ |